Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Kína

In Kína 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen, Xi’an
Életkor
18 év and over
People
1046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
3. fázisTaking people
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Xi’an, Xuzhou, Zhengzhou
Életkor
18 év and over
People
240
Run by
Hutchmed
See details and how to joinNCT07409428
No phaseTaking people
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Where
Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Langfang, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
Életkor
18 év and over
People
300 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07200375
2. fázisNot yet taking people in Kína
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Where
Beijing
Életkor
18 év to 80 év
People
87
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07917624
2/3. fázisTaking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
Életkor
18 év and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
4. fázisTaking people
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
Where
Changchun
Életkor
65 év and over
People
26
Run by
The First Hospital of Jilin University
See details and how to joinNCT07908888
1. fázisTaking people
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Wuhan
Életkor
18 év to 65 év
People
18
Run by
TCRx Therapeutics Co.Ltd
See details and how to joinNCT07260812
2. fázisTaking people
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Where
Shanghai
Életkor
70 év and over
People
38
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07012980
No phaseTaking people
Prospective ctDNA Testing in Large B-Cell Lymphoma
Where
Beijing
Életkor
18 év and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07878351
1. fázisTaking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
Életkor
18 év and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
1. fázisTaking people
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Where
Zhengzhou
Életkor
18 év and over
People
180 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT07424833
3. fázisTaking people
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Életkor
18 év to 75 év
People
282
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07808827
1/2. fázisTaking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
Életkor
18 év and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
1/2. fázisNot yet taking people in Kína
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
Where
Guangzhou, Suzhou
Életkor
18 év to 75 év
People
204
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07818499
1. fázisTaking people
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Where
Tianjin
Életkor
18 év to 75 év
People
18
Run by
Shanghai Exuma Biotechnology Ltd.
See details and how to joinNCT06830031
2. fázisNot yet taking people in Kína
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
Where
Shanghai
Életkor
14 év to 80 év
People
24
Run by
Pengpeng Xu
See details and how to joinNCT07812493
1. fázisTaking people
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Where
Guangzhou, Shanghai
Életkor
18 év and over
People
42
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07570017
1/2. fázisTaking people
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Where
Hangzhou
Életkor
18 év to 75 év
People
70
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07788118
No phaseTaking people
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
Where
Xiamen
Életkor
18 év and over
People
30
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07778212
3. fázisTaking people
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Életkor
18 év to 75 év
People
416
Run by
BeBetter Med Inc
See details and how to joinNCT06792253
2. fázisNot yet taking people in Kína
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
Where
Suzhou
Életkor
18 év and over
People
39
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07774234
No phaseNot yet taking people in Kína
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
Where
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
Életkor
18 év to 80 év
People
58
Run by
WEI XU
See details and how to joinNCT07764601
3. fázisTaking people
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Életkor
18 év to 80 év
People
101
Run by
Sinocelltech Ltd.
See details and how to joinNCT07570823
2. fázisNot yet taking people in Kína
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
Where
Nanjing
Életkor
18 év to 65 év
People
48
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT07744724
2. fázisNot yet taking people in Kína
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
Where
Nanjing
Életkor
18 év to 80 év
People
34
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT07744737